Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)
Purpose: Nivolumab, a programmed death-1 inhibitor, prolonged overall survival compared with docetaxel in two independent phase III studies in previously treated patients with advanced squamous (CheckMate 017; ClinicalTrials.gov identifier: NCT01642004) or nonsquamous (CheckMate 057; ClinicalTrials....
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
October 12, 2017
|
| In: |
Journal of clinical oncology
Year: 2017, Jahrgang: 35, Heft: 35, Pages: 3924-3933 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2017.74.3062 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1200/JCO.2017.74.3062 Verlag, Volltext: http://ascopubs.org/doi/10.1200/JCO.2017.74.3062 
|
| Verfasserangaben: | Leora Horn, David R. Spigel, Everett E. Vokes, Esther Holgado, Neal Ready, Martin Steins, Elena Poddubskaya, Hossein Borghaei, Enriqueta Felip, Luis Paz-Ares, Adam Pluzanski, Karen L. Reckamp, Marco A. Burgio, Martin Kohlhäeufl, David Waterhouse, Fabrice Barlesi, Scott Antonia, Oscar Arrieta, Jérôme Fayette, Lucio Crinò, Naiyer Rizvi, Martin Reck, Matthew D. Hellmann, William J. Geese, Ang Li, Anne Blackwood-Chirchir, Diane Healey, Julie Brahmer, and Wilfried E.E. Eberhardt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580669573 | ||
| 003 | DE-627 | ||
| 005 | 20230427065709.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180904s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2017.74.3062 |2 doi | |
| 035 | |a (DE-627)1580669573 | ||
| 035 | |a (DE-576)510669573 | ||
| 035 | |a (DE-599)BSZ510669573 | ||
| 035 | |a (OCoLC)1341018174 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Horn, Leora |e VerfasserIn |0 (DE-588)1166183505 |0 (DE-627)103013068X |0 (DE-576)510669611 |4 aut | |
| 245 | 1 | 0 | |a Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer |b two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057) |c Leora Horn, David R. Spigel, Everett E. Vokes, Esther Holgado, Neal Ready, Martin Steins, Elena Poddubskaya, Hossein Borghaei, Enriqueta Felip, Luis Paz-Ares, Adam Pluzanski, Karen L. Reckamp, Marco A. Burgio, Martin Kohlhäeufl, David Waterhouse, Fabrice Barlesi, Scott Antonia, Oscar Arrieta, Jérôme Fayette, Lucio Crinò, Naiyer Rizvi, Martin Reck, Matthew D. Hellmann, William J. Geese, Ang Li, Anne Blackwood-Chirchir, Diane Healey, Julie Brahmer, and Wilfried E.E. Eberhardt |
| 264 | 1 | |c October 12, 2017 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 04.09.2018 | ||
| 520 | |a Purpose: Nivolumab, a programmed death-1 inhibitor, prolonged overall survival compared with docetaxel in two independent phase III studies in previously treated patients with advanced squamous (CheckMate 017; ClinicalTrials.gov identifier: NCT01642004) or nonsquamous (CheckMate 057; ClinicalTrials.gov identifier: NCT01673867) non-small-cell lung cancer (NSCLC). We report updated results, including a pooled analysis of the two studies. Methods: Patients with stage IIIB/IV squamous (N = 272) or nonsquamous (N = 582) NSCLC and disease progression during or after prior platinum-based chemotherapy were randomly assigned 1:1 to nivolumab (3 mg/kg every 2 weeks) or docetaxel (75 mg/m2 every 3 weeks). Minimum follow-up for survival was 24.2 months. Results: Two-year overall survival rates with nivolumab versus docetaxel were 23% (95% CI, 16% to 30%) versus 8% (95% CI, 4% to 13%) in squamous NSCLC and 29% (95% CI, 24% to 34%) versus 16% (95% CI, 12% to 20%) in nonsquamous NSCLC; relative reductions in the risk of death with nivolumab versus docetaxel remained similar to those reported in the primary analyses. Durable responses were observed with nivolumab; 10 (37%) of 27 confirmed responders with squamous NSCLC and 19 (34%) of 56 with nonsquamous NSCLC had ongoing responses after 2 years’ minimum follow-up. No patient in either docetaxel group had an ongoing response. In the pooled analysis, the relative reduction in the risk of death with nivolumab versus docetaxel was 28% (hazard ratio, 0.72; 95% CI, 0.62 to 0.84), and rates of treatment-related adverse events were lower with nivolumab than with docetaxel (any grade, 68% v 88%; grade 3 to 4, 10% v 55%). Conclusion: Nivolumab provides long-term clinical benefit and a favorable tolerability profile compared with docetaxel in previously treated patients with advanced NSCLC. | ||
| 700 | 1 | |a Steins, Martin |d 1971- |e VerfasserIn |0 (DE-588)121323900 |0 (DE-627)705384837 |0 (DE-576)292647379 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 35(2017), 35, Seite 3924-3933 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057) |
| 773 | 1 | 8 | |g volume:35 |g year:2017 |g number:35 |g pages:3924-3933 |g extent:10 |a Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057) |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.2017.74.3062 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://ascopubs.org/doi/10.1200/JCO.2017.74.3062 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180904 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 121323900 |a Steins, Martin |m 121323900:Steins, Martin |d 910000 |d 950000 |d 950900 |e 910000PS121323900 |e 950000PS121323900 |e 950900PS121323900 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 6 | ||
| 999 | |a KXP-PPN1580669573 |e 3024713387 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 04.09.2018"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"recId":"1580669573","person":[{"roleDisplay":"VerfasserIn","display":"Horn, Leora","role":"aut","family":"Horn","given":"Leora"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Steins, Martin","given":"Martin","family":"Steins"}],"title":[{"title_sort":"Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer","subtitle":"two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)","title":"Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer"}],"physDesc":[{"extent":"10 S."}],"relHost":[{"title":[{"subtitle":"JCO : an American Society of Clinical Oncology journal","title":"Journal of clinical oncology","title_sort":"Journal of clinical oncology"}],"pubHistory":["1.1983 -"],"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"part":{"extent":"10","volume":"35","text":"35(2017), 35, Seite 3924-3933","issue":"35","pages":"3924-3933","year":"2017"},"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"disp":"Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)Journal of clinical oncology","type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"American Society of Clinical Oncology"}],"recId":"313116962","origin":[{"publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedKey":"1983","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedDisp":"1983-"}],"id":{"issn":["1527-7755"],"zdb":["2005181-5"],"eki":["313116962"]},"physDesc":[{"extent":"Online-Ressource"}]}],"name":{"displayForm":["Leora Horn, David R. Spigel, Everett E. Vokes, Esther Holgado, Neal Ready, Martin Steins, Elena Poddubskaya, Hossein Borghaei, Enriqueta Felip, Luis Paz-Ares, Adam Pluzanski, Karen L. Reckamp, Marco A. Burgio, Martin Kohlhäeufl, David Waterhouse, Fabrice Barlesi, Scott Antonia, Oscar Arrieta, Jérôme Fayette, Lucio Crinò, Naiyer Rizvi, Martin Reck, Matthew D. Hellmann, William J. Geese, Ang Li, Anne Blackwood-Chirchir, Diane Healey, Julie Brahmer, and Wilfried E.E. Eberhardt"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"October 12, 2017"}],"id":{"doi":["10.1200/JCO.2017.74.3062"],"eki":["1580669573"]}} | ||
| SRT | |a HORNLEORASNIVOLUMABV1220 | ||